Tools
Tools
Grossi, Carlota M., Richardson, Kathryn 
ORCID: https://orcid.org/0000-0002-0741-8413, Savva, George M., Fox, Chris ORCID: https://orcid.org/0000-0001-9480-5704, Arthur, Antony, Loke, Yoon K., Steel, Nicholas ORCID: https://orcid.org/0000-0003-1528-140X, Brayne, Carol, Matthews, Fiona E., Robinson, Louise, Myint, Phyo K. and Maidment, Ian D.
(2020)
Increasing prevalence of anticholinergic medication use in older people in England over 20 years: Cognitive Function and Ageing Study I and II.
BMC Geriatrics, 20.
ISSN 1471-2318
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (369kB) | Preview |
Preview |
PDF (Grossi_etal_2020_BMCGeriatrics)
- Published Version
Available under License Creative Commons Attribution. Download (562kB) | Preview |
Abstract
Background: Anticholinergic medication use is linked with increased cognitive decline, dementia, falls and mortality, and their use should be limited in older people. Here we estimate the prevalence of anticholinergic use in England’s older population in 1991 and 2011, and describe changes in use by participant’s age, sex, cognition and disability. Methods: We compared data from participants aged 65+ years from the Cognitive Function and Ageing Studies (CFAS I and II), collected during 1990-1993 (N=7,635) and 2008-2011 (N=7,762). We estimated the prevalence of potent anticholinergic use (Anticholinergic Cognitive Burden [ACB] score=3) and average anticholinergic burden (sum of ACB scores), using inverse probability weights standardised to the 2011 UK population. These were stratified by age, sex, Mini-Mental State Examination score, and activities of daily living (ADL) or instrumental ADL (IADL) disability. Results: Prevalence of potent anticholinergic use increased from 5.7% (95% Confidence Interval [CI] 5.2-6.3%) of the older population in 1990-93 to 9.9% (9.3-10.7%) in 2008-11, adjusted odds ratio of 1.90 (95%CI 1.67 – 2.16). People with clinically significant cognitive impairment (MMSE [Mini Mental State Examination] 21 or less) were the heaviest users of potent anticholinergic in CFAS II (16.5% [95%CI 12.0-22.3%]). Large increases in the prevalence of the use medication with ‘any’ anticholinergic activity were seen in older people with clinically significant cognitive impairment (53.3% in CFAS I to 71.5% in CFAS II). Conclusions: Use of potent anticholinergic medications nearly doubled in England’s older population over 20 years with some of the greatest increases amongst those particularly vulnerable to anticholinergic side-effects.
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |